Head-to-head · WeighScore
Bodi Envi vs Nucific
The verdict
Bodi Envi takes it — 71.8/100 to 56.2/100.
Bodi Envi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bodi Envi is a nationwide telehealth weight-loss provider offering physician-prescribed compounded semaglutide ($179/month) and tirzepatide ($249/month) at flat all-dose pricing with no consultation or…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Bodi Envi | Nucific |
|---|---|---|
| WeighScore | 71.8/100 | 56.2/100 |
| Grade | C | C |
| Scorecard rank | #88 | #417 |
| Semaglutide | $179/mo | Not disclosed |
| Tirzepatide | $249/mo | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #88 · C
Strengths
- Transparent flat pricing: compounded semaglutide $179/month and tirzepatide $249/month, all doses
- No consultation or membership fees
- Free 2-day shipping included; FSA and HSA eligible
- 24/7 secure provider messaging with same-day visits and prescriptions
- Personalized dose titration with side-effect management (Zofran available)
Where it loses points
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
- No insurance billing — cash-pay only
- States served are not explicitly listed (features vary by state)
- No LegitScript certification visible on the site
Graded #417 · C
Strengths
- Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
- Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
- Discloses that featured patients were compensated for their time
- Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
- Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue
Where it loses points
- No price is published anywhere; every option is gated behind a three-minute quiz
- The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
- A BBB Accredited A+ claim is displayed without a link to the BBB profile
- No state list and no named pharmacy, only licensed U.S. pharmacies
- Before-and-after photographs are used alongside compensated testimonials
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.